$25.0M
The Cambridge-based nanomedicine developer has raised capital to expand its laboratory facilities and accelerate product development for its polyNaut technology.
"We are also proud to be working with the Cystic Fibrosis Foundation on one of our key pipeline programmes, underscoring our commitment to advancing treatments for people with cystic fibrosis and other unmet clinical needs. This fundraise marks a pivotal moment in ViaNautis’s journey and we look forward to advancing the field of gene therapy, while creating substantial value for our shareholders."
